These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 17952005

  • 1. Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
    Sadahiro S, Suzuki T, Maeda Y, Ishikawa K, Tanaka Y, Yasuda S, Kamijo A, Makuuchi H, Murayama C.
    Chemotherapy; 2007; 53(6):442-5. PubMed ID: 17952005
    [Abstract] [Full Text] [Related]

  • 2. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
    Ishida H, Ohsawa T, Nakada H, Yokoyama M, Inokuma S, Shirakawa K, Yamada H, Hashimoto D.
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):883-7. PubMed ID: 15222105
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
    Miyoshi T, Kondo K, Toba H, Yoshida M, Fujino H, Kenzaki K, Sakiyama S, Takehisa M, Tangoku A.
    Anticancer Res; 2007 Jun; 27(4C):2641-8. PubMed ID: 17695427
    [Abstract] [Full Text] [Related]

  • 4. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
    Nakagawa T, Tanaka F, Takata T, Matsuoka K, Miyahara R, Otake Y, Yanagihara K, Fukushimab M, Wada H.
    J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
    [Abstract] [Full Text] [Related]

  • 5. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
    Ishida H, Yamada H, Shirakawa K, Nakada H, Ohsawa T, Takeuchi I, Okada N, Yokoyama M, Inokuma S, Suzuki T, Odaka A, Hoshino T, Murata N, Hashimoto D, Itoyama S, Mori T, Matsumoto Y, Miura T.
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
    [Abstract] [Full Text] [Related]

  • 6. [Dihydropyrimidine dehydrogenase activity in urothelial cancer--influence of UFT administration on DPD activity].
    Yano A, Hashimoto K, Okuchi T, Mizoguchi H, Mutaguchi K, Nakamoto T, Usui T.
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1877-83. PubMed ID: 11729480
    [Abstract] [Full Text] [Related]

  • 7. [Clinical significance of TS and DPD activities in colorectal carcinoma as a predictive factor of UFT sensitivity].
    Funahashi K, Koike J, Saito N, Miki T, Matsumoto H, Ryu M, Shiokawa H, Tokuyama T, Goto T, Teramoto T.
    Gan To Kagaku Ryoho; 2004 Feb; 31(2):189-93. PubMed ID: 14997749
    [Abstract] [Full Text] [Related]

  • 8. Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.
    Hisamitsu K, Tsujitani S, Yamaguchi K, Fukuda K, Konishi I, Kaibara N.
    Anticancer Res; 2004 Feb; 24(4):2495-501. PubMed ID: 15330204
    [Abstract] [Full Text] [Related]

  • 9. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
    Tokunaga Y, Sasaki H, Saito T.
    Surgery; 2007 Mar; 141(3):346-53. PubMed ID: 17349846
    [Abstract] [Full Text] [Related]

  • 10. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW, Wang GQ, Wan DS, Pan ZZ, Li S, Chen G, Liao H.
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [Abstract] [Full Text] [Related]

  • 11. Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
    Nio Y, Iguchi C, Kodama H, Itakura M, Hashimoto K, Koike M, Toga T, Maruyama R, Fukushima M.
    Oncol Rep; 2007 Jan; 17(1):153-9. PubMed ID: 17143493
    [Abstract] [Full Text] [Related]

  • 12. [A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration].
    Kai K, Endo Y, Yoshida K, Morikawa T, Nobuhisa T, Watanabe T, Matsumoto Y, Yamada T, Doi Y, Nakashima A, Nagahiro W, Ishizuka S, Sato S, Nakashima A, Nabeyama A.
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):339-41. PubMed ID: 18281779
    [Abstract] [Full Text] [Related]

  • 13. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
    Tsuji T, Sawai T, Takeshita H, Nakagoe T, Hidaka S, Yamaguchi H, Yasutake T, Nagayasu T, Tagawa Y.
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):531-6. PubMed ID: 15309506
    [Abstract] [Full Text] [Related]

  • 14. [Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients].
    Uyama R, Yoshizawa Y, Tajiri T, Endo Y, Mitsuya T, Sanada Y.
    Gan To Kagaku Ryoho; 2006 May; 33(5):625-9. PubMed ID: 16685161
    [Abstract] [Full Text] [Related]

  • 15. Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
    Miyamoto H, Morio A, Izumi H, Yamazaki A, Wang Z, Futagawa T, Sonobe S.
    Anticancer Res; 2003 May; 23(5b):4153-6. PubMed ID: 14666617
    [Abstract] [Full Text] [Related]

  • 16. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.
    Magy Onkol; 2007 May; 51(2):113-25. PubMed ID: 17660867
    [Abstract] [Full Text] [Related]

  • 17. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
    Heslin MJ, Yan J, Weiss H, Shao L, Owens J, Lucas VS, Diasio RB.
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
    [Abstract] [Full Text] [Related]

  • 18. Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity.
    Miyoshi T, Kondo K, Fujino H, Takahashi Y, Sawada N, Sakiyama S, Tsuyuguchi M, Kimura S, Sumitomo M, Monden Y.
    Anticancer Res; 2005 Nov; 25(2A):923-30. PubMed ID: 15868929
    [Abstract] [Full Text] [Related]

  • 19. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B, Guo XD, Zentko S, Harold N, Schuler B, Quinn M, Shapiro J, Grem JL.
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [Abstract] [Full Text] [Related]

  • 20. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
    Etienne-Grimaldi MC, Cardot JM, François E, Renée N, Douillard JY, Gamelin E, Milano G.
    Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.